Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Ann Arbor, Michigan 48109


The purpose of this study is to compare the effect of rosiglitazone versus placebo on soluble proinflammatory markers in peritoneal fluid of women with endometriosis.

Study summary:

The overall goal of this proposal is to assess modulation of immune mechanisms in endometriosis. Endometriosis is a common ailment affecting approximately five million reproductive-aged American women. We will test the efficacy of a novel immunomodulatory drug (peroxisome proliferator activated receptor gamma, PPAR-gamma, agonist), rosiglitazone, to reduce peritoneal fluid cytokine concentrations in women with endometriosis compared with placebo controls (randomized controlled trial). Based on prior studies done by the investigator highlighting the major role of cytokines and the immune system in the genesis or propagation of endometriosis, these experiments could lead to improved translational treatment strategies and a better understanding of endometriosis. Acting through PPAR-gamma, TZDs inhibit proinflammatory cytokines as well as NF-kB, an important nuclear transcription factor for the production of many cytokines. Accordingly, since human endometrial epithelial and stromal cells contain PPAR-gamma, we felt it would be useful to evaluate the influence of a PPAR-gamma ligand, rosiglitazone, on the concentration of specific peritoneal fluid cytokines. Comparison: After the pre-trial screening, eligible subjects with presumed endometriosis and age 18-45 will be consented and randomly assigned to receive either placebo (control) or rosiglitazone, Avandia®, 4 mg daily for 2 weeks. Peritoneal fluid will be collected at the time of surgery and the volume measured. All patients enrolled in the study will have their surgery during the follicular phase of the cycle in order to minimize differences in volume and cytokine concentration due to the cyclical changes. The primary measure will be the peritoneal fluid concentration comparisons of the two groups assessing six different cytokines: interleukin-1 beta, RANTES, tumor necrosis factor-alpha and vascular endothelial growth factor.


Inclusion Criteria: - Healthy women ages 18 - 45 years. - Regular menstrual cycles (24-35 days). - Pelvic pain ≥3 months - Negative pregnancy test - Non-lactating - No prior (<3 months) use of hormonal therapy (<6 mos for depoprovera users) - No history of liver disease - Consent to participate in the study - Endometriosis diagnosed from surgical specimen by routine hematoxylin and eosin staining and histological evaluation (within the past 4 years) Exclusion Criteria: - Major psychiatric conditions or the abuse of alcohol or drugs which would make it difficult for the subject to complete study procedures. - Active or prior infection with hepatitis, human immunodeficiency virus (HIV) infection, or history of high-risk activities (e.g., intravenous [IV] drug abuse) which would increase risk to laboratory personnel. Of note, no testing for hepatitis or HIV will be performed as part of this study and all tissues will be handled and discarded as if they were potentially infected. - Patients with liver dysfunction (elevated liver enzymes >2 times upper limit of normal). - Presence of pre-existing malignancy, including carcinoma of the breast or uterus. - Women with other causes of chronic pelvic pain including infectious, gastrointestinal, musculoskeletal, neurologic or psychiatric. - Elevated white blood cell (WBC) count. - NYHA functional class I-IV heart failure. - Diabetes mellitus. - Known pregnancy or positive pregnancy test.

Study is Available At:

Original ID:




Secondary ID:


Study Acronym:

Brief Title:

Effect of Rosiglitazone on Peritoneal Cytokines in Women With Endometriosis

Official Title:

Endometriosis: Immunomodulation

Overall Status:


Study Phase:

Phase 2/Phase 3



Minimum Age:

18 Years

Maximum Age:

45 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Due to the recent meta-analysis about CV adv

Study Type:


Study Design:

Allocation: Randomized, Endpoint Classification:

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Dan I. Lebovic, MD, MA
Principal Investigator
University of Michigan

Study Dates

Start Date:July 2005
Completion Date:May 2008
Completion Type:Actual
Primary Completion Date:May 2008
Primary Completion Type:Actual
Verification Date:October 2012
Last Changed Date:October 16, 2012
First Received Date:July 18, 2005

Study Outcomes

Outcome Type:Primary Outcome
Measure:Peritoneal fluid cytokine concentrations
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Cytokine quantification
Safety Issues:False
Outcome Type:Secondary Outcome
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Gene array analyses
Safety Issues:False

Study Interventions

Intervention Type:Drug

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:NIH
Agency Type:Lead Sponsor
Agency Name:Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Sample and Retention Information

There are no available Sample and Retention Information

Study References

Reference Type:Reference
Citation:Lebovic DI, Kir M, Casey CL. Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis. Fertil Steril. 2004 Oct;82 Suppl 3:1008-13.

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.